Access clinical resources, education and the latest research to help guide decision-making when considering transplant as a treatment for patients with Acute Myelogenous Leukemia (AML).
Mobile app
Online clinical resources
Recorded webinars
Current AML research
Recently published research
Management of AML
- Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010; 115(3): 453-474. Access Article>
- Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the WHO Classification of Myeloid Neoplasms and Acute Leukemia: rationale and important changes. Blood. 2009; 114(5): 937–951. Access Article>
Transplant in AML
- Litzow MR, Tarima S, Pérez WS, et al. Allogeneic transplantation for therapyrelated myelodysplastic syndrome and acute myeloid leukemia. Blood. 2010; 115(9): 1850-1857. Access Article>
- Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Systematic review and meta-analysis of prospective clinical trials. JAMA. 2009; 301(22): 2349-2361. Access Article>
- Chang CK, Storer BE, Scott BL, et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorder. Blood. 2007; 110(4): 1379-1387. Access Article>
- Karanes C, Nelson GO, Chitphakdithai P, et al. Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant. 2008; 14(9, Suppl. 3). Access Article>
- Oliansky DM, Antin JH, Bennett JM, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant 2009; 15(2): 137-172. Access Article>
Patient eligibility
- Lim ZY, Brand R, Martino R, et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol. 2010; 28(3): 405-411. Access Article>
- McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010; 28(11): 1878-1887. Access Article>
- Krauter J, Wagner K, Stadler M, et al. Prognostic factors in allo-SCT of elderly patients with AML. Bone Marrow Transplant, 2011; 46(4): 545-551. Access Article>
- Walter RB, Gooley TA, Wood BL, et. al. Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia. J Clin Oncol, 2011; 29(9): 1190-1197. Access Article>
Donor selection/outcomes
- Spellman S, Setterholm M, Maiers M, et al. Advances in the selection of HLA-compatible donors: refinements in HLA typing and matching over the first 20 years of the National Marrow Donor Program Registry. Biol Blood Marrow Transplant. 2008; 14(9, Suppl. 3): 37-44. Access Article>
- Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007; 110(13): 4576-4583. Access Article>
- Petersdorf EW, Gooley T, Malkki M, Horowitz M. Clinical significance of donor-recipient HLA matching on survival after myeloablative hematopoietic cell transplantation from unrelated donors. Tissue Antigens. 2007; 69(Suppl. 1): 25-30. Access Article>
- Schetelig J, Bornhäuser M, Schmid C, et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: A report from the Cooperative German Transplant Study Group. J Clin Oncol. 2008; 26(32): 5183-5191.Access Article>
- Moore J, Nivison-Smith I, Goh K, et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant. 2007; 13(5): 601-607. Access Article>
- Gupta V, Tallman MS, He W, et al. Comparable survival after HLA–well matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood. 2010; 16(11): 1829-1848. Access Article>
- Mielcarek M, Storer BE, Sandmaier BM, et al. Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. Biol Blood Marrow Transplant. 2007; 13(12): 1499-1507. Access Article>
Conditioning regimens
- Ringdén O, Labopin M, Ehninger G, et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol. 2009;27(27): 4570-4577. Access Article>
- Field T, Perkins J, Huang Y, et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010; 45(2): 255-260. Access Article>
- Oran B, Giralt S, Saliba R, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant. 2007; 13(4): 454-462. Access Article>
- Sato A, Ooi J, Takahashi S, et al. Unrelated cord blood transplantation after myeloablative conditioning in adults with advanced myelodysplastic syndromes. Bone Marrow Transplant. 2010; 46(2): 257–261. Access Article>
- Devine S, Carter S, Soiffer R, et al. Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous Leukemia in First Remission: Results of the Blood and Marrow Transplant Clinical Trials Network Protocol 0303. Biol Blood Marrow Transplant, 2011; 17(9): 1343-1351. Access Article>
- Alatrash G, de Lima M, Hamerschlak N, et. al. Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life. Biol Blood Marrow Transplant, 2011; 17(10): 1490-1496. Access Article>
- Hegenbart U, Niederwieser D, Sandmaier B, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol. 2006; 24(3): 444-453. Access Article>
Post-transplant care
- Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009; 15 (10): 1143-1238. Access Article>
- Horan JT, Logan BR, Agovi-Johnson M, et. al. Reducing the Risk for Transplantation-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made? J Clin Oncol, 2011; 29(7): 805-813. Access Article>